Risk factors for cefazolin-resistant febrile urinary tract infection in children.
cefazolin
drug resistance
risk factors
urinary tract infections
Journal
Pediatrics international : official journal of the Japan Pediatric Society
ISSN: 1442-200X
Titre abrégé: Pediatr Int
Pays: Australia
ID NLM: 100886002
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
13
10
2021
received:
30
08
2021
accepted:
01
11
2021
pubmed:
6
11
2021
medline:
13
4
2022
entrez:
5
11
2021
Statut:
ppublish
Résumé
Febrile urinary tract infection (fUTI) is a common bacterial infection among children. This study investigated the risk factors for fUTI caused by cefazolin-resistant bacteria in children. The medical records of patients with fUTI hospitalized between April 2014 and March 2020 were retrospectively analyzed. The patients were divided into two groups based on the cefazolin susceptibility of the infection-causing bacteria: cefazolin-resistant and cefazolin-susceptible groups. The records of 80 patients were evaluated. The median age was 5.0 months (range 0.5-119.4 months). Cefazolin-susceptible bacteria were detected in 60 patients (75.0%). Significant differences were noted between the cefazolin-resistant and cefazolin-susceptible groups regarding UTI-related antimicrobial prophylaxis and recurrence of UTI within 3 months (P = 0.0318 and P = 0.00876, respectively). However, no significant differences were observed between these two groups regarding renal anomalies, or UTI history. Logistic regression analysis revealed that the recurrence of UTI within 3 months was an independent, significant risk factor for cefazolin-resistant fUTI (odds ratio 3.81, 95% confidence interval: 1.07-13.5, P = 0.0388). Six patients who were empirically treated with antibiotics ineffective against the infection-causing bacteria recovered from fever before these antibiotics were switched to those effective against the infection-causing bacteria. In children, a recurrence of UTI within 3 months is a risk factor for fUTI caused by cefazolin-resistant bacteria. Recognizing these risk factors before initiating fUTI treatment in children may support treatment with narrower-spectrum antibiotics, such as first-generation cephalosporins (e.g., cefazolin).
Sections du résumé
BACKGROUND
BACKGROUND
Febrile urinary tract infection (fUTI) is a common bacterial infection among children. This study investigated the risk factors for fUTI caused by cefazolin-resistant bacteria in children.
METHODS
METHODS
The medical records of patients with fUTI hospitalized between April 2014 and March 2020 were retrospectively analyzed. The patients were divided into two groups based on the cefazolin susceptibility of the infection-causing bacteria: cefazolin-resistant and cefazolin-susceptible groups.
RESULTS
RESULTS
The records of 80 patients were evaluated. The median age was 5.0 months (range 0.5-119.4 months). Cefazolin-susceptible bacteria were detected in 60 patients (75.0%). Significant differences were noted between the cefazolin-resistant and cefazolin-susceptible groups regarding UTI-related antimicrobial prophylaxis and recurrence of UTI within 3 months (P = 0.0318 and P = 0.00876, respectively). However, no significant differences were observed between these two groups regarding renal anomalies, or UTI history. Logistic regression analysis revealed that the recurrence of UTI within 3 months was an independent, significant risk factor for cefazolin-resistant fUTI (odds ratio 3.81, 95% confidence interval: 1.07-13.5, P = 0.0388). Six patients who were empirically treated with antibiotics ineffective against the infection-causing bacteria recovered from fever before these antibiotics were switched to those effective against the infection-causing bacteria.
CONCLUSIONS
CONCLUSIONS
In children, a recurrence of UTI within 3 months is a risk factor for fUTI caused by cefazolin-resistant bacteria. Recognizing these risk factors before initiating fUTI treatment in children may support treatment with narrower-spectrum antibiotics, such as first-generation cephalosporins (e.g., cefazolin).
Substances chimiques
Anti-Bacterial Agents
0
Cefazolin
IHS69L0Y4T
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15046Informations de copyright
© 2021 Japan Pediatric Society.
Références
National Institute for Health and Clinical Excellence. Urinary tract infection in under 16s: diagnosis and management. National institute for Health and Clinical Excellence, London, UK, 2007.
Subcommittee on Urinary Tract Infection SCoQI, Management, Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics 2011; 128: 595-610.
Chen PC, Chang LY, Lu CY et al. Drug susceptibility and treatment response of common urinary tract infection pathogens in children. J. Microbiol. Immunol. Infect. 2014; 47: 478-83.
Kocak M, Buyukkaragoz B, Celebi Tayfur A et al. Causative pathogens and antibiotic resistance in children hospitalized for urinary tract infection. Pediatr. Int. 2016; 58: 467-71.
Hobbs AL, Shea KM, Daley MJ et al. Are first-generation cephalosporins obsolete? A retrospective, non-inferiority, cohort study comparing empirical therapy with cefazolin versus ceftriaxone for acute pyelonephritis in hospitalized patients. J. Antimicrob. Chemother. 2016; 71: 1665-71.
Abe Y, Wakabayashi H, Ogawa Y et al. Validation of cefazolin as initial antibiotic for first upper urinary tract infection in children. Glob. Pediatr. Health 2016; 3: 2333794x15625297.
Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 24th Informational Supplement, M100-S24. Wayne, PA: CLSI; 24.7
Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013; 48: 452-8.
Mazzariol A, Bazaj A, Cornaglia G. Multi-drug-resistant gram-negative bacteria causing urinary tract infections: a review. J. Chemother. 2017; 29: 2-9.
Kurt-Sukur ED, Ozcakar ZB, Dogan O et al. The changing resistance patterns of bacterial uropathogens in children. Pediatr. Int. 2020; 62: 1058-63.
Flokas ME, Detsis M, Alevizakos M, Mylonakis E. Prevalence of ESBL-producing enterobacteriaceae in paediatric urinary tract infections: a systematic review and meta-analysis. J. Infect. 2016; 73: 547-57.
Kizilca O, Siraneci R, Yilmaz A et al. Risk factors for community-acquired urinary tract infection caused by ESBL-producing bacteria in children. Pediatr. Int. 2012; 54: 858-62.
Paschke AA, Zaoutis T, Conway PH, Xie D, Keren R. Previous antimicrobial exposure is associated with drug-resistant urinary tract infections in children. Pediatrics 2010; 125: 664-72.
Albaramki JH, Abdelghani T, Dalaeen A et al. Urinary tract infection caused by extended-spectrum beta-lactamase-producing bacteria: risk factors and antibiotic resistance. Pediatr. Int. 2019; 61: 1127-32.
Uyar Aksu N, Ekinci Z, Dundar D, Baydemir C. Childhood urinary tract infection caused by extended-spectrum beta-lactamase-producing bacteria: risk factors and empiric therapy. Pediatr. Int. 2017; 59: 176-80.
Larramendy S, Deglaire V, Dusollier P et al. Risk factors of extended-spectrum beta-lactamases-producing Escherichia coli community acquired urinary tract infections: a systematic review. Infect. Drug. Resist. 2020; 13: 3945-55.
Konca C, Tekin M, Uckardes F et al. Antibacterial resistance patterns of pediatric community-acquired urinary infection: overview. Pediatr. Int. 2017; 59: 309-15.
Matsumura Y, Yamamoto M, Nagao M et al. Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-beta-lactamase-producing Escherichia coli bacteremia. Antimicrob. Agents Chemother. 2015; 59: 5107-13.
Wang ME, Lee V, Greenhow TL et al. Clinical response to discordant therapy in third-generation cephalosporin-resistant UTIs. Pediatrics 2020; 145: e20191608.
Mas-Dalmau G, Villanueva López C, Gorrotxategi P et al. Delayed antibiotic prescription for children with respiratory infections: a randomized trial. Pediatrics 2021; 147: e20201323.